These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 9207754)

  • 1. Immunotherapy of lepromin-negative borderline leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta.
    Chaudhury S; Hajra SK; Mukerjee A; Saha B; Majumdar V; Chattapadhya D; Saha K
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):56-62. PubMed ID: 9207754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of far-advanced lepromatous leprosy patients with low-dose convit vaccine along with multidrug therapy (Calcutta trial).
    Majumder V; Mukerjee A; Hajra SK; Saha B; Saha K
    Int J Lepr Other Mycobact Dis; 1996 Mar; 64(1):26-36. PubMed ID: 8627110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of single-dose ROM therapy plus low-dose convit vaccine as an adjuvant for treatment of paucibacillary leprosy patients with a single skin lesion.
    Majumder V; Saha B; Hajra SK; Biswas SK; Saha K
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):283-90. PubMed ID: 11221091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of lepromin positivity following immuno-chemotherapy with Mycobacterium w vaccine and multidrug therapy and its impact on bacteriological clearance in multibacillary leprosy: report on a hospital-based clinical trial with the candidate antileprosy vaccine.
    Sharma P; Kar HK; Misra RS; Mukherjee A; Kaur H; Mukherjee R; Rani R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):259-69. PubMed ID: 10575405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
    Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
    Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine.
    Sharma P; Kar HK; Misra RS; Mukherjee A; Kaur H; Mukherjee R; Rani R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):250-8. PubMed ID: 10575404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and histopathological evaluation of the effect of addition of immunotherapy with Mw vaccine to standard chemotherapy in borderline leprosy.
    Kamal R; Natrajan M; Katoch K; Arora M
    Indian J Lepr; 2012; 84(4):287-306. PubMed ID: 23720894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A longitudinal study of immunologic reactivity in leprosy patients treated with immunotherapy.
    Rada E; Ulrich M; Aranzazu N; Santaella C; Gallinoto M; Centeno M; Rodriguez V; Convit J
    Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):552-8. PubMed ID: 7868953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization potential and reactogenicity of BCG with and without various doses of killed Mycobacterium leprae.
    Gupte MD; Anantharaman DS; De Britto RL; Vallishayee RS; Nagaraju B; Kannan S; Sengupta U
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):340-52. PubMed ID: 1474275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An eight-year field trial on antileprosy vaccines among high-risk household contacts in the Calcutta metropolis.
    Chaudhury S; Hazra SK; Saha B; Mazumder B; Biswas PC; Chattopadhya D; Saha K
    Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):389-94. PubMed ID: 7963911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
    Kaur I; Dogra S; Kumar B; Radotra BD
    Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of combined Mycobacterium w vaccine and 1 year of MDT on multibacillary leprosy patients.
    De Sarkar A; Kaur I; Radotra BD; Kumar B
    Int J Lepr Other Mycobact Dis; 2001 Sep; 69(3):187-94. PubMed ID: 11875762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why relapse occurs in PB leprosy patients after adequate MDT despite they are Mitsuda reactive: lessons form Convit's experiment on bacteria-clearing capacity of lepromin-induced granuloma.
    Chaudhuri S; Hajra SK; Mukherjee A; Saha B; Mazumder B; Chattapadhya D; Saha K
    Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):182-9. PubMed ID: 9728450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-leprosy protective vaccination of rhesus monkeys with BCG or BCG plus heat-killed Mycobacterium leprae: lepromin skin test results.
    Gormus BJ; Baskin GB; Xu K; Ratterree MS; Mack PA; Bohm RP; Meyers WM; Walsh GP
    Lepr Rev; 2002 Sep; 73(3):254-61. PubMed ID: 12449891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy.
    Katoch K; Katoch VM; Natrajan M; Sreevatsa ; Gupta UD; Sharma VD; Shivanavar CT
    Vaccine; 2004 Sep; 22(27-28):3649-57. PubMed ID: 15315844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of bacilliferous BL/LL cases with combined chemotherapy and immunotherapy.
    Katoch K; Katoch VM; Natrajan M; Bhatia AS; Sreevatsa ; Gupta UD; Sharma VD; Shivannavar CT; Patil MA; Bharadwaj VP
    Int J Lepr Other Mycobact Dis; 1995 Jun; 63(2):202-12. PubMed ID: 7602215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A follow-up study of multibacillary Hansen's disease patients treated with multidrug therapy (MDT) or MDT + immunotherapy (IMT).
    Rada E; Ulrich M; Aranzazu N; Rodriguez V; Centeno M; Gonzalez I; Santaella C; Rodriguez M; Convit J
    Int J Lepr Other Mycobact Dis; 1997 Sep; 65(3):320-7. PubMed ID: 9401484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCG immunotherapy as an adjunct to chemotherapy in BL-lL patients--its effect on clinical regression, reaction severity, nerve function, lepromin conversion, bacterial/antigen clearance and 'persister' M. leprae.
    Shetty VP; Mistry NF; Wakade AV; Ghate SD; Capadia GD; Pai VV
    Lepr Rev; 2013 Mar; 84(1):23-40. PubMed ID: 23741880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization potential and reactogenicity of varying doses of BCG plus killed Mycobacterium leprae: an extended study.
    Gupte MD; Vallishayee RS; De Britto LJ; Anantharaman DS
    Int J Lepr Other Mycobact Dis; 1993 Dec; 61(4):563-70. PubMed ID: 8151187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.